Institutional documents and regulatory signals traced to source, keeping official text separate from potential operational implications.
An industry review describes a maturing category in which differentiation increasingly depends on identifiable ingredients and preparations, specific outcomes and communication aligned with the available evidence.
Read the analysis →Removal from the Permissible Ingredients Determination follows a safety review, particularly of severe allergic reactions; the registered-medicines pathway remains available.
Read the analysis →The post-Vitafoods Asia framework aims to separate phospholipid presence or a particle-size measurement from evidence of a genuine liposomal system.
Read the analysis →The authorisation covers the novel food commercially associated with Benicaros, with conditions of use, specifications, warnings and data protection through 2 July 2031.
Read the analysis →Authors report improvements in emotional well-being, gastrointestinal symptoms and sleep quality alongside microbiota and inflammatory-marker changes.
Read the analysis →Pooled estimates indicate mean reductions of 1.65 kg, 0.69 kg/m² in BMI and 0.93 cm in waist circumference; larger signals appeared above 1,000 mg/day.
Read the analysis →Moving from voluntary notification to a requirement could increase transparency and oversight while also affecting timelines, resources and US market-entry planning.
Read the analysis →EFSA considers the Novel Food safe under the proposed uses and levels in foods, infant formula, supplements and foods for special medical purposes.
Read the analysis →The demonstration moves generative AI from sequence prediction to experimental validation of simple organisms while keeping biosafety questions open.
Read the analysis →No clinically relevant changes emerged in vital signs, laboratory parameters or adverse events; tested immune markers remained unchanged.
Read the analysis →The guidance applies to submissions filed from 20 July 2026 and makes the connection between characterisation, proposed use and exposure more explicit.
Read the analysis →The opinion defines the evaluated form, population and use level, providing a concrete regulatory reference for new choline-source development.
Read the analysis →The producer strain could not be conclusively assigned to a species, preventing completion of the Novel Food safety assessment.
Read the analysis →Inclusion of a plant directs documentary research but does not by itself establish that every extract, dose or product is hazardous.
Read the analysis →The work covers new forms, metabolites and molecules with vitamin activity intended for supplements, fortified foods and specific population groups.
Read the analysis →Priorities include Huperzia serrata, guggul, Coleus forskohlii, ginseng, black radish, emodin, chrysophanol and selected Bifidobacterium strains.
Read the analysis →Machine learning and data-driven models can accelerate screening, mechanism interpretation, data integration and optimisation, but depend on experimental quality.
Read the analysis →The Novel Food is proposed for supplements at up to 203.7 mg per day, equivalent to 82.5 mg choline, for people over three years of age.
Read the analysis →Commercial value depends on continuity between the studied strain and the strain that is actually manufactured, stabilised, dosed and communicated.
Read the analysis →The caffeine-free botanical complex is positioned for energy, focus and mood applications, with dsm-firmenich supporting clinical, regulatory and commercial development.
Read the analysis →The project combines nutrivigilance, reports and botanical screening to identify priorities for further investigation, not an automatic list of prohibited ingredients.
Read the analysis →Combining diet, biomarkers, multi-omics, microbiome and wearables is not enough: models must generalise and show value in real populations and settings.
Read the analysis →Six ingredients or ingredient groups and three botanical substances are identified as signals requiring further investigation, not as risks that have already been conclusively established.
Read the analysis →Age, education, urbanisation and dietary composition change the footprint of diets; targeted interventions may be more informative than uniform approaches.
Read the analysis →Anonymous product purchasing reduces the risk that certification reflects only manufacturer-selected samples and makes product quality more legible to buyers.
Read the analysis →Topic pages connect current reporting with the permanent archive.
Receive the editorial selection or request a free introductory conversation on using AI tools and automation in nutraceutical work.
GMA